AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12075743
Drug: Alternating treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating treatment group (A) received docetaxel 100 mg/m2 on days 1 and 43, alternating with cisplatin 100 mg/m2 on day 22 and vinorelbine 30 mg/m2 on days 22, 29, and 36.
Trial: 12075743
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (B) received cisplatin 80 mg/m2 on days 1, 22, and 43, and vinorelbine 30 mg/m2 once a week from day 1 to day 57.
Trial: 9935086
Drug: 10% glycolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glycolic acid cream twice daily (n=25)
Trial: 9935086
Drug: Hydroquinone 4%
RxNorm normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroquinone 4% cream qHS and tretinoin 0.025% cream twice daily (n=25)
Trial: 24392599
Drug: Twice-daily insulin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily insulin lispro mix 75/25 (LM75/25)
Trial: 23567001
Drug: Once-daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily insulin glargine
Trial: 19172535
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg micronized progesterone vaginally three times per day starting in the afternoon of oocyte retrieval until the morning of embryo transfer, in addition to standard hCG luteal-phase support.
Trial: 17062301
Drug: AZD3582 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3582 375 mg
Trial: 17062301
Drug: AZD3582 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3582 750 mg
Trial: 17062301
Drug: AZD3582 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3582 1500 mg
Trial: 17062301
Drug: AZD3582 2250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3582 2250 mg
Trial: 12920841
Drug: Postoperative patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 ropivacaine + 2 mg.L‐1 fentanyl (Group RF)
Trial: 12920841
Drug: Postoperative patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 bupivacaine + 2 mg.L‐1 fentanyl (Group BF)
Trial: 12920841
Drug: Postoperative patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 bupivacaine + 80 mg.L‐1 morphine (Group BM)
Trial: 12920841
Drug: General‐epidural anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General‐epidural anesthesia and patient‐controlled intravenous analgesia with 0.5 g.L‐1 morphine (Group EM)
Trial: 12920841
Drug: Postoperative patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patient‐controlled intravenous analgesia with 0.5 g.L‐1 morphine (Group M)
Trial: 10941607
Drug: Psychological support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological support associated with pharmacological treatment (benzodiazepine, gamma‐hydroxybutyric acid)
Trial: 3839018
Drug: Efamol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efamol treatment (prostaglandin synthesis precursor)
Trial: 29705519
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist anakinra
Trial: 16181747
Drug: Pristinamycin (PRI)
RxNorm normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pristinamycin (PRI) 3 g daily for 7 to 10 days
Trial: 16181747
Drug: Amoxicillin (AMX)
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (AMX) 3 g daily for 7 to 10 days
Trial: 16181747
Drug: Pristinamycin (PRI)
RxNorm normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pristinamycin (PRI) and Amoxicillin (AMX)
Trial: 7720443
Drug: 10-cm stapled
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-cm stapled colonic pouch low rectal anastomosis
Trial: 30224345
Drug: Panobinostat 40
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat 40 mg triweekly for 2 weeks with bicalutamide 50 mg/day in 3-week cycles (A arm)
Trial: 30224345
Drug: Panobinostat 20
RxNorm normalized name: panobinostat 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 20 mg triweekly for 2 weeks with bicalutamide 50 mg/day in 3-week cycles (B arm)
Trial: 30224345
Drug: High-dose bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose bicalutamide (historical control)
Trial: 27896644
Drug: El Sistema
RxNorm normalized name: hydroxypropyl cellulose (type EL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: El Sistema music program (treatment group)
Trial: 26655003
Drug: Subconjunctival bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival bevacizumab (1.25 mg/0.05 ml) 1 week before surgery
Trial: 26655003
Drug: Subconjunctival normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival normal saline (1.25 mg/0.05 ml) 1 week before surgery
Trial: 20086314
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg calcium plus 800 IU vitamin D(3)/d (Ca+VD group)
Trial: 20086314
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg calcium/d (Ca group)
Trial: 16101342
Drug: Smoking reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking reduction intervention with counselling and/or nicotine replacement therapy (NRT)
Trial: 12051574
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g b.i.d. dosing of Nitazoxanide
Trial: 12051574
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g b.i.d. dosing of Nitazoxanide
Trial: 10086859
Drug: Moisturizer applied
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizer applied 3 times daily for 4 weeks on one forearm
Trial: 2327750
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg once daily for 5 days
Trial: 2327750
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg twice daily for 5 days
Trial: 31540574
Drug: Fabomotizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fabomotizole (10 mg thrice a day)
Trial: 28762756
Drug: Intranasal 24
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 24 IU Oxytocin
Trial: 23430709
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of patch and oral NRT
Trial: 23430709
Drug: Inhalator to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalator to deliver oral NRT
Trial: 18076801
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate controlled-released tablet
Trial: 18076801
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride sustained-released tablet
Trial: 28537501
Drug: Oxycodone controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone controlled release (CR)
Trial: 7516641
Drug: Thymopentin +
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin + G‐CSF
Trial: 2556079
Drug: Daptomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (1 mg/kg)
Trial: 2556079
Drug: Daptomycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (2 mg/kg)
Trial: 2556079
Drug: Daptomycin and
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin and Amikacin (500 mg)
Trial: 2556079
Drug: Daptomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (1 or 2 mg/kg)
Trial: 2556079
Drug: Vancomycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (500 mg)
Trial: 2556079
Drug: Daptomycin and
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin and Amikacin combination
Trial: 4154124
Drug: S.A.I.M.R. antivenom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S.A.I.M.R. antivenom (average dose 15.2 ml)
Trial: 4154124
Drug: Behringwerke antivenom
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behringwerke antivenom (average dose 37.9 ml)
Trial: 21563035
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (400 microgram every second hour, total 1600 microgram)
Trial: 21563035
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (healthy subjects with no previous use of beta2‐agonists)
Trial: 15925911
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg orally daily
Trial: 15925911
Drug: Beclomethasone 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone 400 ug local sprays daily
Trial: 9832000
Drug: Meningococcal C
RxNorm normalized name: meningococcal conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal C conjugate vaccine (group 1, n = 69)
Trial: 9832000
Drug: Meningococcal polysaccharide
RxNorm normalized name: meningococcal polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal polysaccharide vaccine (group 2, n = 72)
Trial: 9832000
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B virus vaccine (group 3, n = 70)
Trial: 8130046
Drug: morphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.15 mg kg‐1 and metoclopramide 10 mg
Trial: 8130046
Drug: morphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.15 mg kg‐1 and glycopyrronium 5 micrograms kg‐1
Trial: 8130046
Drug: morphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.15 mg kg‐1 and hyoscine 5 micrograms kg‐1
Trial: 26733277
Drug: Aripiprazole (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (initial dose 5-10 mg per day followed by flexible doses 5-15 mg per day)
Trial: 26733277
Drug: Risperidone (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (initial dose 2-4 mg per day followed by flexible doses 4-6 mg per day)
Trial: 25184356
Drug: Sapropterin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin 200 to 400 mg BID
Trial: 20005545
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyperoxia and handgrip
Trial: 17574795
Drug: Modified therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified therapeutic community (TC) track with psychoeducational seminar, trauma-informed addictions treatment, and case management
Trial: 18052566
Drug: Venlafaxine 75-150
RxNorm normalized name: venlafaxine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75-150 mg/day
Trial: 11262776
Drug: Reconstructive procedures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reconstructive procedures in surgical treatment of tumors
Trial: 9715201
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) 80 mg/400 mg orally three times daily for 10 days
Trial: 2648609
Drug: Tear solution
RxNorm normalized name: glycerin Ophthalmic Solution [Oasis Tears]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tear solution with polyvinyl alcohol 1.4% m/v preserved with 0.5% m/v chlorobutanol
Trial: 2648609
Drug: Tear solutions
RxNorm normalized name: glycerin Ophthalmic Solution [Oasis Tears]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tear solutions without chlorobutanol
Trial: 15542065
Drug: Platelets from
RxNorm normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelets from NIDDM patients in a medium containing 180 mg/dL glucose
Trial: 15542065
Drug: Platelets from
RxNorm normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelets from NIDDM patients in a medium containing 90 mg/dL glucose
Trial: 8158885
Drug: Control (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (other antihypertensive treatments excluding ACE inhibitors)
Trial: 30232856
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (puncturing specific acupoints with filiform needles, once every other day for 8 weeks)
Trial: 30232856
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment (Omeprazole capsules, 20 mg twice a day for 8 weeks)
Trial: 25321941
Drug: LipiFlow (automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipiFlow (automated thermodynamic treatment)
Trial: 22386977
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (home-based physical therapy program without vibration training)
Trial: 20143872
Drug: 1.2 mg
RxNorm normalized name: RNA 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg of folic acid daily for 12 weeks
Trial: 16573801
Drug: Lansoprazole 90
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 90 mg, 6 mg/h
Trial: 16573801
Drug: Lansoprazole orally
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole orally disintegrating tablet 60 mg every 6 h
Trial: 16573801
Drug: Lansoprazole 120
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 120 mg, 9 mg/h
Trial: 16573801
Drug: Lansoprazole 120
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 120 mg, 6 mg/h
Trial: 1558237
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both early active motion and continuous passive motion
Trial: 24361229
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with assessment of response at week 12 using anatomic imaging (CT/MRI)
Trial: 24361229
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with assessment of response at week 12
Trial: 24361229
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with assessment of response at week 12 for ERMS
Trial: 24361229
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with assessment of response at week 12 for ARMS
Trial: 646600
Drug: Videotape immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotape immediate feedback during rehabilitation sessions (four sessions at weekly intervals)
Trial: 31852491
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (Control)
Trial: 27883997
Drug: CBT4BN (Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT4BN (Internet-based manualized CBT group therapy)
Trial: 27883997
Drug: CBTF2F (traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBTF2F (traditional face-to-face group therapy)
Trial: 25827507
Drug: Low-dose lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose lithium added to optimized treatment (OPT)
Trial: 21029208
Drug: narrow-band UVB
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: narrow-band UVB monotherapy (PT)
Trial: 19899672
Drug: Psychotherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapeutic treatment using empatho-techniques
Trial: 8196254
Drug: Digoxin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (35 mg/day)
Trial: 8196254
Drug: Captopril (0.31
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (0.31 mg/day)
Trial: 26204531
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow mononuclear cell intracoronary transplantation (mean dose of 8.19 ± 4.43 x 10(6) CD34+ cells)
Trial: 22049165
Drug: Graded intakes
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded intakes of protein (0.1-2.56 g · kg(‐1) · d(‐1))
Trial: 22049165
Drug: Current DRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current DRI recommendations for protein (0.76 g · kg(‐1) · d(‐1))
Trial: 7957448
Drug: MSP (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP (20 mg base of mefloquine/kg body weight)
Trial: 7957448
Drug: MSP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP plus primaquine (0.75 mg/kg)
Trial: 3069760
Drug: sulconazole nitrate
RxNorm normalized name: Sulconazole Nitrate
DrugBank: Sulconazole (DB06820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sulconazole nitrate 1% cream applied twice daily for 14 days
Trial: 3069760
Drug: miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: miconazole nitrate 2% cream applied twice daily for 14 days
Trial: 23187936
Drug: MVC 150
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVC 150 mg once daily
Trial: 23187936
Drug: TDF/FTC 300/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC 300/200 mg once daily + ATV/r 300/100 mg once daily
Trial: 22328095
Drug: Janthinobacterium lividum
RxNorm normalized name: Ricinus lividus oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Janthinobacterium lividum treatment
Trial: 16284083
Drug: 17beta-estradiol supplementation
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol supplementation (ES; 2 mg/day)
Trial: 15331898
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser treatment (contact and hybrid)
Trial: 9497875
Drug: IGF‐I infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I infusion (43.7 pmol/kg/min or 20 micrograms/kg/h)
Trial: 9497875
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (3.4 pmol/kg/min or 0.5 mU/kg/min)
Trial: 9497875
Drug: IGF‐I infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I infusion
Trial: 9497875
Drug: IGF‐I and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I and insulin infusions
Trial: 8298916
Drug: No patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No patch angioplasty (Control)
Trial: 29081326
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) exposure therapy, approximately 1 hour
Trial: 26635305
Drug: Higher level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher level of amino acids (1.2 g/kg)
Trial: 26635305
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid intake (0.8 g/kg)
Trial: 25465451
Drug: Oral discussion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral discussion and written handout outlining the risks of otoplasty
Trial: 25465451
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral dialog of the surgical risks
Trial: 23419912
Drug: Non‐therapeutic dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐therapeutic dose of intermittent ultrasound
Trial: 19002337
Drug: Light-fractionated aminolaevulinic
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-fractionated aminolaevulinic acid photodynamic therapy (PDT)